Identification

Name
Tegaserod
Accession Number
DB01079  (APRD00096)
Type
Small Molecule
Groups
Investigational, Withdrawn
Description

Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. On March 30, 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves. The FDA alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke. [Wikipedia]

Structure
Thumb
Synonyms
  • 1-(((5-Methoxyindol-3-yl)methylene)amino)-3-pentylguanidine
  • tégasérod
  • tegaserodum
External IDs
SDZ HTF 919
Product Ingredients
IngredientUNIICASInChI Key
Tegaserod maleateE5XNT3RF5A189188-57-6CPDDZSSEAVLMRY-FEQFWAPWSA-N
International/Other Brands
Zelmac / Zelnorm
Categories
UNII
458VC51857
CAS number
145158-71-0
Weight
Average: 301.394
Monoisotopic: 301.190260381
Chemical Formula
C16H23N5O
InChI Key
IKBKZGMPCYNSLU-RGVLZGJSSA-N
InChI
InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+
IUPAC Name
N'-[(E)-[(5-methoxy-1H-indol-3-yl)methylidene]amino]-N-pentylguanidine
SMILES
CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2

Pharmacology

Indication

Provides relief from the symptoms of irritable bowel syndrome including chronic idiopathic constipation.

Structured Indications
Not Available
Pharmacodynamics

Tegaserod is indicated for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation. Irritable bowel syndrome with constipation and chronic idiopathic constipation are both lower gastrointestinal dysmotility disorders. Clinical investigations have shown that both motor and sensory functions of the gut appear to be altered in patients suffering from irritable bowel syndrome (IBS), while in patients with chronic idiopathic constipation, reduced intestinal motility is the predominant cause of the condition. Both the enteric nervous system, which acts to integrate and process information in the gut, and 5-hydroxytryptamine (5-HT, serotonin) are thought to represent key elements in the etiology of both IBS and idiopathic constipation. Approximately 95% of serotonin is found throughout the gastrointestinal tract, primarily stored in enterochromaffin cells but also in enteric nerves acting as a neurotransmitter. Serotonin has been shown to be involved in regulating motility, visceral sensitivity and intestinal secretion. Investigations suggest an important role of serotonin Type-4 (5-HT4) receptors in the maintenance of gastrointestinal functions in humans. 5-HT4 receptor mRNA has been found throughout the human gastrointestinal tract.

Mechanism of action

Tegaserod is a 5-HT4 receptor partial agonist that binds with high affinity at human 5-HT4 receptors, whereas it has no appreciable affinity for 5-HT3 or dopamine receptors. It has moderate affinity for 5-HT1 receptors. Tegaserod, by acting as an agonist at neuronal 5-HT4 receptors, triggers the release of further neurotransmitters such as calcitonin gene-related peptide from sensory neurons. The activation of 5-HT4 receptors in the gastrointestinal tract stimulates the peristaltic reflex and intestinal secretion, as well as inhibits visceral sensitivity.

TargetActionsOrganism
A5-hydroxytryptamine receptor 4
antagonist
partial agonist
Human
U5-hydroxytryptamine receptor 2B
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
Absorption

Rapidly absorbed after oral administration, with an absolute bioavailability of approximately 10%.

Volume of distribution
  • 368 ± 223 L
Protein binding

98%

Metabolism

Tegaserod is metabolized mainly via two pathways. The first is a presystemic acid catalyzed hydrolysis in the stomach followed by oxidation and conjugation which produces the main metabolite of tegaserod, 5-methoxyindole-3-carboxylic acid glucuronide. The main metabolite has negligible affinity for 5-HT4 receptors in vitro. The second metabolic pathway of tegaserod is direct glucuronidation which leads to generation of three isomeric N-glucuronides.

Route of elimination

Approximately two-thirds of the orally administered dose of tegaserod is excreted unchanged in the feces, with the remaining one-third excreted in the urine, primarily as the main metabolite.

Half life

11 ± 5 hours

Clearance
  • 77 +/- 15 L/h [IV administration]
Toxicity

Oral LD50 in rat is 2000 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Tegaserod can be increased when it is combined with Abiraterone.Approved
AmiodaroneThe metabolism of Tegaserod can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Tegaserod.Approved, Investigational
ArtemetherThe metabolism of Tegaserod can be decreased when combined with Artemether.Approved
AtomoxetineThe metabolism of Tegaserod can be decreased when combined with Atomoxetine.Approved
BetaxololThe metabolism of Tegaserod can be decreased when combined with Betaxolol.Approved
BupropionThe metabolism of Tegaserod can be decreased when combined with Bupropion.Approved
CelecoxibThe metabolism of Tegaserod can be decreased when combined with Celecoxib.Approved, Investigational
ChloroquineThe metabolism of Tegaserod can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe metabolism of Tegaserod can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Tegaserod can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Tegaserod can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Tegaserod can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Tegaserod can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Tegaserod can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Tegaserod can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Tegaserod can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Tegaserod can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Tegaserod can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Tegaserod can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Tegaserod can be decreased when combined with Cocaine.Approved, Illicit
DarifenacinThe metabolism of Tegaserod can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Tegaserod can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Tegaserod can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Tegaserod can be decreased when combined with Desipramine.Approved
DiphenhydramineThe metabolism of Tegaserod can be decreased when combined with Diphenhydramine.Approved
DosulepinThe metabolism of Tegaserod can be decreased when combined with Dosulepin.Approved
DronedaroneThe metabolism of Tegaserod can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Tegaserod can be decreased when combined with Duloxetine.Approved
EliglustatThe metabolism of Tegaserod can be decreased when combined with Eliglustat.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tegaserod.Approved
FluoxetineThe metabolism of Tegaserod can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Tegaserod can be decreased when combined with Fluvoxamine.Approved, Investigational
HaloperidolThe metabolism of Tegaserod can be decreased when combined with Haloperidol.Approved
ImipramineThe metabolism of Tegaserod can be decreased when combined with Imipramine.Approved
IndinavirThe metabolism of Tegaserod can be decreased when combined with Indinavir.Approved
IsoniazidThe metabolism of Tegaserod can be decreased when combined with Isoniazid.Approved
KetoconazoleThe metabolism of Tegaserod can be decreased when combined with Ketoconazole.Approved, Investigational
LopinavirThe metabolism of Tegaserod can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Tegaserod can be decreased when combined with Lorcaserin.Approved
LumefantrineThe metabolism of Tegaserod can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Tegaserod can be decreased when combined with Manidipine.Approved, Investigational
MethadoneThe metabolism of Tegaserod can be decreased when combined with Methadone.Approved
MethotrimeprazineThe metabolism of Tegaserod can be decreased when combined with Methotrimeprazine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tegaserod.Approved, Investigational
MidostaurinThe metabolism of Tegaserod can be decreased when combined with Midostaurin.Approved
MirabegronThe metabolism of Tegaserod can be decreased when combined with Mirabegron.Approved
NevirapineThe metabolism of Tegaserod can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Tegaserod can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Tegaserod can be decreased when combined with Nilotinib.Approved, Investigational
PanobinostatThe serum concentration of Tegaserod can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Tegaserod can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Tegaserod can be decreased when it is combined with Peginterferon alfa-2b.Approved
PromazineThe metabolism of Tegaserod can be decreased when combined with Promazine.Approved, Vet Approved
QuinidineThe metabolism of Tegaserod can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Tegaserod can be decreased when combined with Quinine.Approved
RanolazineThe metabolism of Tegaserod can be decreased when combined with Ranolazine.Approved, Investigational
RitonavirThe metabolism of Tegaserod can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Tegaserod can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Tegaserod can be decreased when combined with Ropinirole.Approved, Investigational
SertralineThe metabolism of Tegaserod can be decreased when combined with Sertraline.Approved
StiripentolThe metabolism of Tegaserod can be decreased when combined with Stiripentol.Approved
TerbinafineThe metabolism of Tegaserod can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tegaserod.Approved, Withdrawn
TiclopidineThe metabolism of Tegaserod can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Tegaserod can be decreased when combined with Tipranavir.Approved, Investigational
TranylcypromineThe metabolism of Tegaserod can be decreased when combined with Tranylcypromine.Approved
VenlafaxineThe metabolism of Tegaserod can be decreased when combined with Venlafaxine.Approved
ZiprasidoneThe metabolism of Tegaserod can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take before a meal, to increase absorption, take 30 minutes before a meal.

References

Synthesis Reference

Sundaram Venkataraman, Srinivasulu Gudipati, Brahmeshwararao Mandava Venkata Naga, Goverdhan Banda, Radhakrishna Singamsetty, "Process for preparing form I of tegaserod maleate." U.S. Patent US20050272802, issued December 08, 2005.

US20050272802
General References
Not Available
External Links
KEGG Drug
D06056
PubChem Compound
5362436
PubChem Substance
46506519
ChemSpider
10609889
BindingDB
79022
ChEBI
51043
ChEMBL
CHEMBL76370
Therapeutic Targets Database
DAP001526
PharmGKB
PA130413154
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Tegaserod
ATC Codes
A06AX06 — Tegaserod
FDA label
Download (634 KB)
MSDS
Download (58.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentSymptomatic Gastroespohageal Reflux Disease1
2TerminatedNot AvailableDiabetic Gastropathy1
2, 3TerminatedTreatmentOccasional Constipation1
3CompletedTreatmentChronic Constipation1
3CompletedTreatmentGastroesophageal Reflux Disease (GERD)2
3CompletedTreatmentHeartburn / Indigestion1
3CompletedTreatmentIndigestion5
3CompletedTreatmentOccasional Constipation1
3TerminatedTreatmentConstipation Predominant / Irritable Bowel Syndrome (IBS-C)1
3TerminatedTreatmentOpioid Induced Constipation (OIC)2
4CompletedTreatmentChronic Constipation1
4CompletedTreatmentIBS-C and IBS With Mixed Bowel Habits1
4CompletedTreatmentOccasional Constipation1
4TerminatedTreatmentChronic Constipation1
4TerminatedTreatmentDiabetes / Gastroparesis1
4WithdrawnTreatmentConstipation and Dyspepsia1
Not AvailableNo Longer AvailableNot AvailableChronic Idiopathic Constipation / Constipation Predominant Irritable Bowel Syndrome1
Not AvailableTerminatedTreatmentChronic Diseases / Occasional Constipation1
Not AvailableUnknown StatusTreatmentOccasional Constipation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5510353No1993-04-262013-04-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)155 °CNot Available
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0288 mg/mLALOGPS
logP2.76ALOGPS
logP2.95ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)15.24ChemAxon
pKa (Strongest Basic)8.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area85.29 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity110.25 m3·mol-1ChemAxon
Polarizability34.96 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9973
Blood Brain Barrier+0.7842
Caco-2 permeable-0.5939
P-glycoprotein substrateSubstrate0.921
P-glycoprotein inhibitor INon-inhibitor0.8978
P-glycoprotein inhibitor IINon-inhibitor0.959
Renal organic cation transporterInhibitor0.5488
CYP450 2C9 substrateNon-substrate0.8522
CYP450 2D6 substrateNon-substrate0.5492
CYP450 3A4 substrateNon-substrate0.6565
CYP450 1A2 substrateNon-inhibitor0.53
CYP450 2C9 inhibitorNon-inhibitor0.7096
CYP450 2D6 inhibitorNon-inhibitor0.7807
CYP450 2C19 inhibitorNon-inhibitor0.6372
CYP450 3A4 inhibitorNon-inhibitor0.8954
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7654
Ames testNon AMES toxic0.5434
CarcinogenicityNon-carcinogens0.7783
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.6038 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5123
hERG inhibition (predictor II)Non-inhibitor0.8334
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indoles
Direct Parent
Indoles
Alternative Parents
Anisoles / Alkyl aryl ethers / Substituted pyrroles / Heteroaromatic compounds / Guanidines / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Imines / Hydrocarbon derivatives
Substituents
Indole / Anisole / Alkyl aryl ether / Substituted pyrrole / Benzenoid / Pyrrole / Heteroaromatic compound / Guanidine / Azacycle / Ether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
guanidines, indoles, carboxamidine, hydrazines (CHEBI:51043)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Partial agonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR4
Uniprot ID
Q13639
Uniprot Name
5-hydroxytryptamine receptor 4
Molecular Weight
43760.975 Da
References
  1. Camilleri M: Review article: tegaserod. Aliment Pharmacol Ther. 2001 Mar;15(3):277-89. [PubMed:11207504]
  2. Kamm MA: Review article: the complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther. 2002 Mar;16(3):343-51. [PubMed:11876686]
  3. Corsetti M, Tack J: Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome. Expert Opin Pharmacother. 2002 Aug;3(8):1211-8. [PubMed:12150698]
  4. Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. [PubMed:15466450]
  5. Cole P, Rabasseda X: Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome. Drugs Today (Barc). 2004 Dec;40(12):1013-30. [PubMed:15645012]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. [PubMed:15466450]
  2. McCullough JL, Armstrong SR, Hegde SS, Beattie DT: The 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat. Pharmacol Res. 2006 Apr;53(4):353-8. Epub 2006 Feb 21. [PubMed:16495076]
  3. Greenwood-Van Meerveld B, Campbell-Dittmeyer K, Johnson AC, Hicks GA: 5-HT2B receptors do not modulate sensitivity to colonic distension in rats with acute colorectal hypersensitivity. Neurogastroenterol Motil. 2006 May;18(5):343-5. [PubMed:16629860]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. [PubMed:15466450]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. [PubMed:15466450]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Ismair MG, Kullak-Ublick GA, Blakely RD, Fried M, Vavricka SR: Tegaserod inhibits the serotonin transporter SERT. Digestion. 2007;75(2-3):90-5. Epub 2007 May 18. [PubMed:17510552]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:46